MBX Capital

– Contraline, Inc. has closed $10.7m in its Series A financing.
– The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies.
– The infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.
– The ADAM hydrogel is injected into the vas deferens through a quick and minimally invasive outpatient procedure, where it’s designed to block the flow of sperm.
– This trial on ADAM is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years.

– Digital health platform, Mae, announced its $1.3M pre-seed funding round led by SteelSky Ventures.
– Other investors in this pre-seed round include Avestria Ventures, MBX Capital, Rhia Ventures.
– This list of investors represents participation from three of the most prominent venture capital funds in the women’s health space, underscoring a commitment to and belief in Mae’s innovative delivery model and its potential to drive health equity and positive outcomes for Black expectant mothers and their babies.
– Mae was founded by CEO Maya Hardigan, following 15-years in digital health product innovation, most recently at Pfizer.